This is a treatment that uses a special protein called hirudin to help prevent blood clots. Doctors might use it for certain heart or blood problems.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Hirudin therapy means treating or preventing blood clots with anticoagulants (blood thinners) based on hirudin, a protein first found in the saliva of medicinal leeches. Hirudin blocks thrombin, the enzyme that turns the blood protein fibrinogen into the strands of fibrin that hold a clot together. Because it acts on thrombin directly, it belongs to a group called direct thrombin inhibitors. The medicines used in hospitals are made in the lab rather than taken from leeches. Lepirudin and desirudin were manufactured copies of the natural protein. Bivalirudin (sold as Angiomax and as generics) is a shorter, synthetic version built on hirudin's design, and it is the hirudin-type drug in common use in the US today. This page is about these injected medicines, not about placing live leeches on the skin. Dabigatran (Pradaxa), a pill taken for long-term clot prevention, blocks the same enzyme but is a different kind of molecule.
Bivalirudin is approved for people having percutaneous coronary intervention (PCI), the catheter procedure that opens a narrowed heart artery with a balloon and usually a stent. It is one of the options a cardiology team can choose, alongside heparin, to keep clots from forming on the catheters and the treated artery during the procedure. Hirudin-type drugs also matter for people with heparin-induced thrombocytopenia (HIT), an immune reaction to heparin that lowers the platelet count and, paradoxically, raises the risk of dangerous clots. These drugs do not react with the antibodies that drive HIT, so they can be used when heparin has to be stopped. Bivalirudin's label covers PCI in people with HIT; for treating HIT more generally, hematology guidelines list it among several non-heparin choices, along with argatroban and others. Desirudin was once used to prevent leg vein clots after hip replacement, but it is no longer sold in the US, and lepirudin was taken off the market in 2012.
Bivalirudin is given only in the hospital, through an IV line. For PCI, the team gives a starting dose (a bolus) followed by a continuous drip for the length of the procedure, with the amount set by body weight. A few minutes after the bolus, they check the activated clotting time (ACT), a quick bedside blood test of how long blood takes to clot, and give extra drug if the blood is not thin enough. It has been studied in people also taking aspirin, which is standard during these procedures. After an emergency procedure for a major heart attack (STEMI, the type that shows a characteristic pattern on the heart tracing), the drip may continue for up to about four hours. When a hirudin-type drug is used for HIT, the dose is adjusted using repeated clotting tests. Kidney function is checked because the dose is lowered when the kidneys clear the drug more slowly, including in people on dialysis.
Most people do not feel the drug itself. It starts working as soon as it enters the vein, and its effect fades quickly: clotting tests return to normal about an hour after the drip stops. That short action is one reason teams choose it, since the blood thinning can be switched off soon after the procedure. Bleeding is the most common side effect, so nurses watch for it while the drug is running and afterward, checking blood pressure and blood counts. After an emergency procedure for a heart attack, people stay at least a day in a hospital equipped to treat a sudden blockage of the stent.
For PCI, bivalirudin has been compared with heparin in many large trials. Pooled analyses of these trials in people with acute coronary syndromes (heart attacks and unstable angina) found that bivalirudin caused less major bleeding and fewer transfusions. Overall rates of death, repeat heart attack and stroke were similar between the two drugs. Results have varied with how heparin was used in the comparison group and whether other clot-preventing drugs were added, so neither drug is clearly best for every patient. The evidence for older hirudins is more limited. In HIT, lepirudin was linked to fewer deaths, amputations and new clots than in earlier patients treated without it, but that comparison was not randomized. In a randomized trial after hip replacement, desirudin prevented more deep vein clots than enoxaparin, a common injected blood thinner, with similar safety. Hirudin is also being studied for stroke and other conditions, often in new formulations, but this work is largely in laboratory or early clinical stages and is not an established treatment.
Bleeding is the main risk, as with any blood thinner. Major bleeding, including bleeding inside the body, occurred in a few percent of people in the trials, and a drop in blood pressure or blood count during treatment is treated as possible bleeding until proven otherwise. Bivalirudin is not used in someone who is already bleeding heavily or who has had an allergic reaction to it. While the drip is running and in the hours after, tell the nurse right away about bleeding, growing swelling at the catheter site, or new chest pain. In people treated for a major heart attack, early clotting inside a new stent happened more often with bivalirudin than with heparin in the first hours (about 1 in 80 people versus 1 in 500 in the label's data). This is why monitoring continues after the procedure and why the drip may be extended. Reduced kidney function lets the drug build up, so the dose is lowered. The older recombinant hirudins carried a distinctive risk: about half of people given lepirudin developed antibodies to it, and rare severe allergic reactions (anaphylaxis) occurred, especially with repeat exposure. Bivalirudin rarely triggers antibodies. Anyone who has received lepirudin in the past should tell their care team, because a non-hirudin anticoagulant may be the safer choice.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Hirudin Therapy, what's helped you, or ask the community a question.